EUVIMEDEUVIMED entdecken
Crossref

Baseline FDG PET/CT–Defined Axillary Burden Predicts Axillary Pathologic Complete Response After Neoadjuvant Therapy in Breast Cancer

Mehmet Tarık Tatoğlu iD, İlker Nihat Ökten, Ebru Ibisoglu, Tuçe Söylemez Akkurt, Ferda Yerdelen Tatoğlu, Hatice Uslu, Hakan Baysal

Nuklearmedizin - NuclearMedicine · 01.06.2026 · 65 (03) · 207-216

DOI: 10.1055/a-2825-4883 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.06.2026. Verfasst von Mehmet Tarık Tatoğlu und 6 weiteren Autor:innen. Beteiligte Einrichtung: TC Saglik Bakanligi Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi, Nuclear Medicine, Türkiye, Istanbul. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Neoadjuvant Therapy, Breast Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Predicting axillary pathologic complete response (pCR) after neoadjuvant systemic therapy (NST) may enable risk-adapted axillary management in clinically node-positive breast cancer (BC), but practical baseline PET-derived predictors are limited.

Methods

Single-center retrospective cohort of consecutive cN+, M0 patients with baseline [18F]FDG PET/CT–reported axillary nodal metastasis treated with NST and surgery (complete-case n=115). Axillary pCR was defined as no residual invasive carcinoma in axillary lymph nodes; isolated tumor cells and/or micrometastases were classified as non-pCR. Two prespecified ridge-penalized logistic models combined routine clinical variables with baseline PET-defined axillary burden as (i) hypermetabolic ALN count (Model A) or (ii) limited (1–3) versus advanced (≥4) burden group (Model B). Stratified 5-fold cross-validation generated out-of-fold (OOF) predictions; AUC, Brier score, and logistic recalibration slope/intercept were bootstrapped on OOF predictions (2000 resamples).

Results

Axillary pCR occurred in 59/115 (51.3%). Discrimination was good: AUC 0.80 (95% CI 0.72–0.88) for Model A and 0.79 (95% CI 0.71–0.87) for Model B. Calibration was acceptable (bootstrap-mean slope/intercept ≈1.10/0.04 and 1.08/0.03, respectively). Greater baseline PET-defined axillary extent was associated with lower odds of pCR; molecular subtype and neoadjuvant anti-HER2 therapy remained strongly associated with response.

Conclusion

Prespecified ridge models combining routine clinical variables with baseline [18F]FDG PET/CT–defined axillary burden showed good internal performance for predicting axillary pCR. External validation is required before response-adapted clinical use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyFluorodeoxyglucose F18Neoadjuvant TherapyBreast NeoplasmsHumansFemalePathologic Complete ResponseAxillaRetrospective StudiesLymphatic MetastasisRadiopharmaceuticalsMiddle AgedTreatment OutcomeAdultAged

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • TC Saglik Bakanligi Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi, Nuclear Medicine, Türkiye, Istanbul.
  • TC Sağlık Bakanlığı Göztepe Prof Dr Süleyman Yalçın Şehir Hastanesi, Department of Medical Oncology, Türkiye, Istanbul.
  • Göztepe Prof Dr Süleyman Yalçın Şehir Hastanesi, Nuclear Medicine, Türkiye, Istanbul.
  • TC Sağlık Bakanlığı Göztepe Prof Dr Süleyman Yalçın Şehir Hastanesi, Department of Pathology, Türkiye, Istanbul.
  • İstanbul Medeniyet Üniversitesi Tip Fakültesi, Department of Pathology, Türkiye, Istanbul.
  • Istanbul University Faculty of Economics, Department of Econometrics, Türkiye, Istanbul.

ORCID-Profile: Mehmet Tarık Tatoğlu

Zitieren

APA

Tatoğlu, M. T., Ökten, İ. N., Ibisoglu, E., Söylemez Akkurt, T., Yerdelen Tatoğlu, F., Uslu, H., & Baysal, H. (2026). Baseline FDG PET/CT–Defined Axillary Burden Predicts Axillary Pathologic Complete Response After Neoadjuvant Therapy in Breast Cancer. Nuklearmedizin - NuclearMedicine, 65(03), 207-216. https://doi.org/10.1055/a-2825-4883

Vancouver

Tatoğlu MT, Ökten İN, Ibisoglu E, Söylemez Akkurt T, Yerdelen Tatoğlu F, Uslu H, et al. Baseline FDG PET/CT–Defined Axillary Burden Predicts Axillary Pathologic Complete Response After Neoadjuvant Therapy in Breast Cancer. Nuklearmedizin - NuclearMedicine. 2026;65(03):207-216. doi:10.1055/a-2825-4883

BibTeX
@article{Tatolu2026,
  author = {Tatoğlu, Mehmet Tarık and Ökten, İlker Nihat and Ibisoglu, Ebru and Söylemez Akkurt, Tuçe and Yerdelen Tatoğlu, Ferda and Uslu, Hatice and Baysal, Hakan},
  title = {Baseline FDG PET/CT–Defined Axillary Burden Predicts Axillary Pathologic Complete Response After Neoadjuvant Therapy in Breast Cancer},
  journal = {Nuklearmedizin - NuclearMedicine},
  year = {2026},
  volume = {65},
  number = {03},
  pages = {207--216},
  doi = {10.1055/a-2825-4883}
}
Kostenlos starten →